var data={"title":"Apixaban: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Apixaban: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/512790?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=apixaban-patient-drug-information\" class=\"drug drug_patient\">see &quot;Apixaban: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15868354\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Discontinuation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Premature discontinuation of any oral anticoagulant, including apixaban, increases the risk of thrombotic events. If anticoagulation with apixaban is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Spinal/Epidural hematoma:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Epidural or spinal hematomas may occur in patients treated with apixaban who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include use of indwelling epidural catheters; concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants; a history of traumatic or repeated epidural or spinal punctures; a history of spinal deformity or spinal surgery; optimal timing between the administration of apixaban and neuraxial procedures is not known.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor patients frequently for signs and symptoms of neurologic impairment. If neurologic compromise is noted, urgent treatment is necessary.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881499\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Eliquis;</li>\n      <li>Eliquis Starter Pack</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471661\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Eliquis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14478981\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Anticoagulant, Factor Xa Inhibitor;</li>\n      <li>\n        Direct Oral Anticoagulant (DOAC)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14479016\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Deep venous thrombosis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Treatment:</b> 10 mg twice daily for 7 days followed by 5 mg twice daily.<b> Note:</b> LMWH is preferred over oral anticoagulation for treatment of patients <i>with</i> cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Duration of therapy:</i> Optimal duration of therapy is unknown and is dependent on many factors, such as whether provoking events were present, patient risk factors for recurrence and bleeding, and individual preferences; however, ACCP guidelines recommend the following:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Long-term (first 3 months): </i>3 months is the minimum duration for most patients <i>without</i> cancer following their first episode of VTE (provoked or unprovoked) (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Extended therapy (after first 3 months and no scheduled stop date):</i> May be considered in patients with unprovoked first DVT of the leg who do not have a high bleeding risk. Extended therapy is recommended in patients with unprovoked second DVT of the leg who do not have a high risk of bleeding. In patients <i>with</i> cancer, extended therapy is recommended, although high bleeding risk confers a lower grade of recommendation. All patients receiving extended therapy should be reassessed at periodic intervals for continuing use of therapy (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reduction in the risk of recurrence:</b> 2.5 mg twice daily after at least 6 months of treatment for DVT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):</b> Oral: 5 mg twice daily <b>unless</b> patient has any 2 of the following: Age &ge;80 years, body weight &le;60 kg, or serum creatinine &ge;1.5 mg/dL, then reduce dose to 2.5 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative venous thromboprophylaxis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hip replacement surgery: 2.5 mg twice daily beginning 12 to 24 hours postoperatively; duration: 35 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Knee replacement surgery: 2.5 mg twice daily beginning 12 to 24 hours postoperatively; duration: 12 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary embolism (PE):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i> 10 mg twice daily for 7 days followed by 5 mg twice daily.<b> Note:</b> LMWH is preferred over oral anticoagulation for treatment of patients <i>with</i> cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Duration of therapy:</i> Optimal duration of therapy is unknown and is dependent on many factors, such as whether provoking events were present, patient risk factors for recurrence and bleeding, and individual preferences; however, ACCP guidelines recommend the following:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Long-term (first 3 months): </i>3 months is the minimum duration for most patients <i>without</i> cancer following their first episode of VTE (provoked or unprovoked) (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Extended therapy (after first 3 months and no scheduled stop date):</i> May be considered in patients with unprovoked first PE who do not have a high bleeding risk. Extended therapy is recommended in patients with unprovoked PE who do not have a high risk of bleeding. In patients <i>with</i> cancer, extended therapy is recommended, although high bleeding risk confers a lower grade of recommendation. All patients receiving extended therapy should be reassessed at periodic intervals for continuing use of therapy (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reduction in the risk of recurrence:</b> 2.5 mg twice daily after at least 6 months of treatment for PE</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>\n        <b>Conversion from one anticoagulant to another: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from warfarin to apixaban:</i> Discontinue warfarin and initiate apixaban when INR is &lt;2</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from apixaban to warfarin:</i> <b>Note:</b> Apixaban affects the INR; measuring the INR during coadministration with warfarin therapy may not be useful for determining an appropriate dose of warfarin</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If continuous anticoagulation is necessary, discontinue apixaban and begin both a parenteral anticoagulant with warfarin when the next dose of apixaban is due; discontinue parenteral anticoagulant when INR reaches an acceptable range. Alternatively, some recommend continuing apixaban during initiation of warfarin or other vitamin K antagonist (VKA) at usual starting doses until INR &ge;2, then discontinue apixaban. During concomitant therapy, initiating INR testing on day 3 and just prior to each dose of apixaban is also recommended (Eliquis Canadian product labeling 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from apixaban to other non-warfarin anticoagulants (oral or parenteral):</i> Discontinue apixaban and begin taking the new non-warfarin anticoagulant at the usual time of the next scheduled dose of apixaban.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from other non-warfarin anticoagulants (oral or parenteral) to apixaban:</i> Discontinue the other non-warfarin anticoagulant and begin taking apixaban at the usual time of the next scheduled dose of the other non-warfarin anticoagulant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment of apixaban with concomitant medications:</b> For patients receiving dual strong CYP3A4 and P-glycoprotein inhibitors (eg, ketoconazole, itraconazole, ritonavir) and apixaban doses &gt;2.5 mg twice daily, reduce apixaban dose by 50%. Note: Avoid concomitant use with dual strong CYP3A4 and P-glycoprotein inhibitors if patient is already taking apixaban 2.5 mg twice daily or patient meets 2 of the following criteria: Age &ge;80 years, body weight &le;60 kg, or serum creatinine &ge;1.5 mg/dL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14479017\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Refer to adult dosing. Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): If patient is &ge;80 years of age <b>and</b> <i>either</i> weighs &le;60 kg or has a serum creatinine &ge;1.5 mg/dL, then reduce dose to 2.5 mg twice daily.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14479013\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Deep vein thrombosis (DVT), pulmonary embolism (PE), reduction in the risk of recurrent DVT and PE</b>\n      <b>:</b> No dosage adjustment is recommended by the manufacturer for any degree of renal impairment. However, patients with a serum creatinine &gt;2.5 mg/dL or CrCl &lt;25 mL/minute (as determined by Cockcroft-Gault equation) were excluded from the clinical trials (Agnelli 2013a; Agnelli 2013b). Some experts avoid use in severe renal impairment (Hull 2018).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD requiring hemodialysis: According to the manufacturer, no dosage adjustment necessary. Some experts avoid use in ESRD requiring hemodialysis (Hull 2018). Also see <b>Note:</b> ESRD requiring hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum creatinine &lt;1.5 mg/dL: No dosage adjustment necessary <i>unless</i> &ge;80 years of age <b>and</b> body weight &le;60 kg, then reduce dose to 2.5 mg twice daily (also refer to adult dosing).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum creatinine &ge;1.5 mg/dL <b>and</b> <i>either</i> &ge;80 years of age <b>or</b> body weight &le;60 kg: 2.5 mg twice daily. <b>Note:</b> Patients with a serum creatinine &gt;2.5 mg/dL or CrCl &lt;25 mL/minute (as determined by Cockcroft-Gault equation) were excluded from clinical trials (Connolly 2011; Granger 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe or ESRD <b>not</b> requiring hemodialysis: Warfarin remains the anticoagulant of choice (AHA/ACC/HRS [January 2014]). However, in patients who cannot take warfarin, some experts consider apixaban to be a reasonable alternative (Manning 2018).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD requiring hemodialysis: According to the manufacturer, no dosage adjustment necessary <b>unless</b> if &ge;80 years of age or body weight &le;60 kg, then reduce to 2.5 mg twice daily. More recent pharmacokinetic data suggests use of a reduced dose (ie, 2.5 mg twice daily) for patients with ESRD requiring thrice weekly hemodialysis sessions since the approved 5 mg twice-daily dosing resulted in significant supratherapeutic exposure (Mavrakanas 2017). However, these data have still not determined whether the long-term use of this dosing will reduce systemic embolic events and bleeding risk in patients with ESRD requiring hemodialysis (Fanikos 2017); some experts avoid anticoagulation in this population unless risk of thromboembolism is very high (KDIGO [Herzog 2011], Manning 2018). In patients with ESRD requiring hemodialysis, in whom a decision is made to anticoagulate, warfarin remains the anticoagulant of choice (AHA/ACC/HRS [January 2014]). Also see <b>Note:</b> ESRD requiring hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative (hip or knee replacement) venous thromboprophylaxis:</b> No dosage adjustment is recommended by the manufacturer for any degree of renal impairment. However, it should be noted that patients with either clinically significant renal impairment (ADVANCE-1 [Lassen 2009]), impaired renal function (ADVANCE-2 [Lassen 2010b]), or CrCl &lt;30 mL/minute (as determined by Cockcroft-Gault equation) (ADVANCE-3 [Lassen 2010a]) were excluded from the respective clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD requiring hemodialysis: According to the manufacturer, no dosage adjustment necessary. Also see <b>Note:</b> ESRD requiring hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>\n      <b>ESRD requiring hemodialysis: </b>Not dialyzable to minimally dialyzable (AUC decreased by 14% over 4 hours) (NCS/SCCM [Frontera 2016]; Wang 2016). The above manufacturer's recommendations are made solely on a single-dose pharmacokinetic and pharmacodynamic (anti-factor Xa activity) study in only 8 patients (Wang 2016). Clinical efficacy and long-term safety studies have <b>not</b> been done in this population; therefore, due to limited available data, use with caution (AHA [Raval 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>\n        <b>Additional recommendations</b>:</i> Geriatric patients &ge;65 years of age: CrCl &lt;25 mL/minute: Avoid use due to increased risk of bleeding (Beers Criteria [AGS 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14479014\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh class A): No dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate impairment (Child-Pugh class B): There are no dosage adjustments provided in manufacturer's labeling; use with caution (limited clinical experience in these patients).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): Use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46888094\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">The International Society on Thrombosis and Haemostasis (ISTH) 2016 guideline suggests avoiding the use of apixaban (and other direct oral anticoagulants) in patients with a BMI &gt;40 kg/m<sup>2</sup> or weight &gt;120 kg due to the lack of clinical data in this population. If used in a patient with a BMI &gt;40 kg/m<sup>2</sup> or weight &gt;120 kg, ISTH suggests measuring peak and trough levels using an antifactor Xa assay or mass spectrometry. If drug level is below the expected range, ISTH suggests changing to a vitamin K antagonist rather than adjusting the dose of apixaban (ISTH [Martin 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15869945\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Eliquis: 2.5 mg, 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Eliquis Starter Pack: 5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881025\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15869944\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at http://packageinserts.bms.com/medguide/medguide_eliquis.pdf, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14479020\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Administer without regard to meals. After hip/knee replacement, initial dose should be administered 12 to 24 hours postoperatively. If patient unable to swallow whole tablets, may crush 5 mg or 2.5 mg tablets and suspend in 60 mL of water, D5W, or apple juice or mix with applesauce; administer immediately. For delivery through a nasogastric tube, crushed tablets may be suspended in 60 mL of water or D5W followed by immediate delivery. Crushed tablets are stable in water, D5W, apple juice, and applesauce for up to 4 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14478984\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Deep vein thrombosis:</b> Treatment of deep vein thrombosis; to reduce the risk of recurrent deep vein thrombosis following initial therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>The American College of Chest Physicians (ACCP) guidelines for VTE suggest apixaban (or dabigatran, rivaroxaban, or edoxaban) over a vitamin K antagonist as long-term anticoagulant therapy in patients with DVT of the leg <b>and</b> without cancer (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonvalvular atrial fibrillation:</b> To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines for the management of AF recommend oral anticoagulation for patients with nonvalvular AF or atrial flutter with prior stroke, TIA, or a CHA<sub>2</sub>DS<sub>2</sub>-VASc score &ge;2. As an alternative to warfarin, apixaban may also be used for at least 3 weeks prior and 4 weeks after cardioversion in patients with AF or atrial flutter of &ge;48 hours duration or when the duration is unknown (AHA/ACC/HRS [January 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative venous thromboprophylaxis following hip or knee replacement surgery:</b> Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in patients who have undergone hip or knee replacement surgery</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary embolism:</b> Treatment of pulmonary embolism; to reduce the risk of recurrent pulmonary embolism following initial therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>The American College of Chest Physicians (ACCP) guidelines for VTE suggest apixaban (or dabigatran, rivaroxaban, or edoxaban) over a vitamin K antagonist as long-term anticoagulant therapy in patients with PE <b>and</b> without cancer (Kearon 2012; Kearon 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50287188\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Recurrent stroke/transient ischemic attacks (prevention)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14478979\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Apixaban may be confused with axitinib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14478992\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Hematologic &amp; oncologic: Hemorrhage (1% to 12%; major: &le;3%; clinically relevant nonmajor bleeding: 2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (3%), gingival hemorrhage (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hematuria (&le;2%), hypermenorrhea (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (3%), bruise (1% to 2%), hematoma (1% to 2%), postprocedural hemorrhage (&le;1%), rectal hemorrhage (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (&le;4%), hemoptysis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, abnormal uterine bleeding, acute posthemorrhagic anemia, allergic edema, anal hemorrhage, anaphylaxis, conjunctival hemorrhage, gastrointestinal hemorrhage, genital bleeding, hematemesis, hematochezia, hematoma, hematoma at injection site, hemophthalmos, hemorrhoidal bleeding, hypersensitivity, hypotension, incision site hemorrhage, increased serum alkaline phosphatase, increased serum AST, increased serum bilirubin, intracranial hemorrhage, melena, muscle hemorrhage, occult blood in urine, perioperative blood loss, periorbital edema (Ahmad 2018), periorbital hematoma, petechia, postoperative hematoma (incision site), postprocedural hemorrhage, puncture site bleeding, retinal hemorrhage, skin rash, syncope, thrombocytopenia, vaginal hemorrhage, wound hemorrhage, wound secretion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14478988\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Severe hypersensitivity reaction (ie, anaphylaxis) to apixaban or any component of the formulation; active pathological bleeding</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling: </i>Hypersensitivity to apixaban or any component of the formulation; clinically-significant active bleeding (including gastrointestinal bleeding); lesions or conditions at increased risk of clinically-significant bleeding (eg, cerebral infarct [ischemic or hemorrhagic], active peptic ulcer disease with recent bleeding; patients with spontaneous or acquired impairment of hemostasis); hepatic disease associated with coagulopathy and clinically-relevant bleeding risk; concomitant systemic treatment with agents that are strong inhibitors of both CYP3A4 and P-glycoprotein (P-gp); concomitant treatment with any other anticoagulant including unfractionated heparin (except at doses used to maintain patency of central venous or arterial catheter), low molecular weight heparins, heparin derivatives (eg, fondaparinux), and oral anticoagulants including warfarin, dabigatran, rivaroxaban except when transitioning to or from apixaban therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14478989\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: May increase the risk of bleeding, including severe and potentially fatal bleeding. Concomitant use of drugs that affect hemostasis increases the risk of bleeding. Discontinue therapy with active pathological hemorrhage and promptly evaluate for bleeding source. No specific antidote for apixaban reversal exists. Apixaban is highly protein-bound; therefore, hemodialysis is ineffective. Depending on the bleeding severity, activated oral charcoal should be considered if ingestion occurred within 1 to 2 hours of presentation. The following alternative options may also be considered depending specific clinical scenario: 4-factor unactivated prothrombin concentrate (PCC) (eg, Kcentra) or 4-factor activated prothrombin complex concentrate (aPCC) (eg, FEIBA). Some studies and case reports have shown moderate success in correcting coagulation tests with some of these agents; however, correction of coagulation tests does not imply reversal of the anticoagulation effect of the medication (AHA/ASA [Hemphill 2015; EHRA [Heidbuchel 2015]; NCS/SCCM [Frontera 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: <b>[US Boxed Warning]: Premature discontinuation of any oral anticoagulant, including apixaban, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.</b> When used to prevent stroke in patients with nonvalvular atrial fibrillation, an increased risk of stroke was observed upon transition from apixaban to warfarin in clinical trials. If apixaban must be discontinued for reasons other than bleeding or completion of a course of therapy, consider the use of another anticoagulant. In patients with non-valvular atrial fibrillation who had an acute ischemic stroke while receiving a DOAC (eg, apixaban), guidelines generally support withholding oral anticoagulation until 1 to 2 weeks after the ischemic stroke (time frame may vary with shorter times for transient ischemic attack or small, non-disabling stroke and longer times for moderate-to-severe stroke) (AHA/ASA [Kernan 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute coronary syndrome (ACS): In a clinical trial evaluating the use of apixaban in addition to standard antiplatelet therapy to reduce the risk of recurrent ischemic events post-ACS, an increased incidence of major bleeding (including intracranial and fatal bleeding) without any significant clinical benefit was observed (Alexander 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in moderate impairment (Child-Pugh class B) as there is limited clinical experience in these patients; dosing recommendations cannot be provided. Use in severe hepatic impairment (Child-Pugh class C) is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Systemic exposure increases with worsening renal function. Bleeding risk may be increased in severe renal impairment (CrCl &lt;15 to 29 mL/minute); use with caution. Patients with significant renal impairment (eg, CrCl &lt;30 mL/minute) were excluded from clinical trials. Dosage reduction is recommended for patients with nonvalvular atrial fibrillation and 2 of the 3 following risk factors: Serum creatinine &ge;1.5 mg/dL, age &ge;80 years, or weight &le;60 kg. Compared to warfarin, apixaban has been shown to be associated with less major bleeding among all ranges of estimated GFRs as determined by initial serum creatinine; however, patients with a serum creatinine &gt;2.5 mg/dL or CrCl &lt;25 mL/minute (as determined by Cockcroft-Gault equation) were excluded from the analysis (Hohnloser 2012). Use with caution in patients on hemodialysis; limited information is available. In patients who develop acute kidney injury during use, closely monitor or consider switching to an alternative anticoagulant due to an increased risk of bleeding in this population (AHA [Raval 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Valvular disease: Safety and efficacy have not been established in patients with prosthetic heart valves or significant rheumatic heart disease (eg, mitral stenosis); use is not recommended. Non-valvular atrial fibrillation is defined as atrial fibrillation that occurs in the absence of rheumatic mitral valve disease, mitral valve repair, or prosthetic heart valve (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acutely ill medical patients: In acutely ill patients (eg, heart failure, respiratory failure) at risk for venous thromboembolism (VTE) receiving apixaban for extended VTE prophylaxis, an increased incidence of major bleeding without greater efficacy was observed with extended apixaban therapy (eg, 30 days) versus low molecular weight heparin (enoxaparin) therapy for 1 to 2 weeks (Goldhaber 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Systemic exposure is increased ~32% in patients &gt;65 years of age; however, dose reductions are not required. Dosage reduction is recommended for patients with nonvalvular atrial fibrillation who are &ge;80 years of age <b>and</b> <i>either</i> weigh &le;60 kg or with a serum creatinine &ge;1.5 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: In hemodynamically unstable patients with acute PE or patients with PE requiring thrombolysis or pulmonary embolectomy, the use of apixaban is not recommended as an alternative to unfractionated heparin for initial treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Body weight: Systemic exposure may be increased by 20% to 30% in patients &lt;50 kg and decreased by 20% to 30% in patients &gt;120 kg; dosage reduction is recommended for patients with nonvalvular atrial fibrillation weighing &le;60 kg <b>and</b> <i>either</i> &ge;80 years of age or with a serum creatinine &ge;1.5 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Spinal or epidural hematoma: <b>[US Boxed Warning]: Spinal or epidural hematomas resulting in long-term or permanent paralysis may occur with neuraxial anesthesia (epidural or spinal anesthesia) or spinal/epidural puncture; the risk is increased by the use of indwelling epidural catheters with concomitant administration of other drugs that affect hemostasis (eg, NSAIDS, platelet inhibitors, other anticoagulants), in patients with a history of traumatic or repeated epidural or spinal punctures, a history of spinal deformity or surgery, or if optimal timing between the administration of apixaban and neuraxial procedures is not known. Consider the potential benefit versus risk prior to neuraxial intervention in patients who are anticoagulated or scheduled to be anticoagulated for thromboprophylaxis.</b> In patients who receive both apixaban and neuraxial anesthesia, avoid removal of epidural or intrathecal catheter for at least 24 hours following last apixaban dose; avoid apixaban administration for at least 5 hours following catheter removal. If traumatic puncture occurs, delay administration of apixaban for at least 48 hours. Monitor frequently for signs of neurologic impairment (eg, numbness/weakness of legs, bowel/bladder dysfunction). If neurologic impairment is noted, prompt treatment is necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14642518\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2, CYP1A2 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14642516\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=85642&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Apixaban may enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <b> Exceptions: </b>Acenocoumarol; Warfarin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiplatelet Agents (P2Y12 Inhibitors): May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of Apixaban.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Apixaban.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Apixaban.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Apixaban.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of Apixaban. Management: Consider alternatives to this combination when possible.  Apixaban dose adjustments may be required when used with systemic fusidic acid.  Patients using this combination should be monitored extra closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhibitors of CYP3A4 (Strong) and P-glycoprotein: May increase the serum concentration of Apixaban. Management: US labeling recommends a 50% apixaban dose reduction in patients who would otherwise receive 5 or 10 mg twice daily, and avoiding in patients who would otherwise receive 2.5 mg twice daily. Canadian labeling lists any combined use as contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naproxen: May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Naproxen may increase the serum concentration of Apixaban.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Apixaban.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14478997\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may increase levels/effects of apixaban. Management: Advise patients who consume grapefruit juice during therapy to use caution; monitor for increased effects (eg, bleeding). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15868175\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14478985\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Data are insufficient to evaluate the safety of oral factor Xa inhibitors during pregnancy; use during pregnancy should be avoided (Bates 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14478987\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if apixaban is excreted in breast milk. Apixaban is not recommended for use in breast-feeding women; use of alternative anticoagulants is preferred (Bates 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14479022\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function and CBC prior to initiation, when clinically indicated, and at least annually in all patients (AHA/ACC/HRS [January 2014]; AHA [Raval 2017]), hepatic function; signs of bleeding. Routine monitoring of coagulation tests is not required.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When converting from apixaban to a vitamin K antagonist (VKA), it has been recommended to perform INR testing just prior to each dose of apixaban beginning on day 3 of concurrent therapy with the VKA (Eliquis Canadian product labeling 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50847165\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Routine coagulation testing is <b>not</b> required or necessary for DOACs. (There are currently no FDA-approved assays or calibration reagents available.)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In clinical situations when assessment of the anticoagulant effect is useful (eg, acute care, periprocedural settings), evaluating a recent creatinine clearance and time since the last dose was ingested is usually sufficient for guiding clinical decisions. No commonly used coagulation tests can definitively exclude the presence of clinically relevant serum concentrations. A prolonged PT suggests clinically relevant serum concentrations are present, but normal PT and aPTT values cannot rule out the presence of apixaban. If available, the preferred test to rule out clinically significant serum concentrations and quantify anticoagulant effect is antifactor Xa activity calibrated specifically for apixaban (undetectable anti-Xa activity likely excludes clinically relevant drug concentrations). An antifactor Xa assay calibrated for low molecular weight heparin can rule out clinically relevant drug concentrations, but is not useful for quantification. (ACC [Tomaselli 2017]; AHA [Raval 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14479000\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of free and clot-bound factor Xa (FXa). FXa, as part of the prothrombinase complex consisting also of factor Va, calcium ions, and phospholipid, catalyzes the conversion of prothrombin to thrombin. Thrombin both activates platelets and catalyzes the conversion of fibrinogen to fibrin. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14479002\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: 3 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: ~21 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~87%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic predominantly via CYP3A4/5 and to a lesser extent via CYP1A2, 2C8, 2C9, 2C19, and 2J2 to inactive metabolites; O-demethylation and hydroxylation are the major sites of transformation; substrate of P-glycoprotein (P-gp) and breast cancer resistant protein (BCRP)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~12 hours (8 to 15 hours) (AHA [Raval 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 3 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~27% as parent drug); feces (biliary and direct intestinal excretion)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570441\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Eliquis Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (60): $502.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (74): $620.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Eliquis Starter Pack Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (74): $620.17</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059506\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Elikvis (UA);</li>\n      <li>Eliquis (AE, AR, AT, AU, BB, BE, BH, BR, CH, CN, CO, CY, CZ, DE, DK, EE, FR, GB, HK, HR, HU, ID, IE, IL, IS, JP, KR, LT, LU, LV, MT, MY, NL, NO, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, TH, TR, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Agnelli G, Buller HR, Cohen A, et al, &ldquo;Apixaban for Extended Treatment of Venous Thromboembolism,&rdquo; <i>N Engl J Med</i>, 2013a, 368(8):699-708.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/23216615/pubmed\" target=\"_blank\" id=\"23216615\">23216615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Agnelli G, Buller HR, Cohen A, et al, &ldquo;Oral Apixaban for the Treatment of Acute Venous Thromboembolism,&rdquo; <i>N Engl J Med</i>, 2013b [epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/23808982/pubmed\" target=\"_blank\" id=\"23808982\">23808982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28913641\"></a>Ahmad A, Steinhilber S. Periorbital edema from apixaban treatment. <i>J Gen Intern Med</i>. 2018;33(2):232.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28913641/pubmed\" target=\"_blank\" id=\"28913641\">28913641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alexander JH, Lopes RD, James S, et al, &ldquo;Apixaban With Antiplatelet Therapy After Acute Coronary Syndrome,&rdquo; <i>N Engl J Med</i>, 2011, 365(8):699-708.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/21780946/pubmed\" target=\"_blank\" id=\"21780946\">21780946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, et al, &ldquo;Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial,&rdquo; <i>Circulation</i>, 2009, 119(22):2877-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/19470889/pubmed\" target=\"_blank\" id=\"19470889\">19470889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bates SM, Greer IA, Middeldorp S, et al. &ldquo;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e691-736.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/22315276/pubmed\" target=\"_blank\" id=\"22315276\">22315276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Connolly SJ, Eikelboom J, Joyner C, et al, &ldquo;Apixaban in Patients With Atrial Fibrillation,&rdquo; <i>N Engl J Med</i>, 2011, 364(9):806-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/21309657/pubmed\" target=\"_blank\" id=\"21309657\">21309657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Culebras A, Mess&eacute; SR, Chaturvedi S, et al. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2014;82(8):716-724.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/24566225/pubmed\" target=\"_blank\" id=\"24566225\">24566225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27957279\"></a>Curto A, Albaladejo A. Implications of apixaban for dental treatments. <i>J Clin Exp Dent</i>. 2016;8(5):e611-e614.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/27957279/pubmed\" target=\"_blank\" id=\"27957279\">27957279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eliquis (apixaban) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Escolar G, Arellano-Rodrigo E, Reverter JC, et al, &ldquo;Reversal of Apixaban Induced Alterations of Hemostasis by Different Coagulation Factor Concentrates: Studies in vitro With Circulating Human Blood,&rdquo; Circulation, 2012, 126(4):520-1. Available at http://circ.ahajournals.org/content/early/2012/06/20/CIR.0b013e3182611cc222718802</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fanikos J, Burnett AE, Mahan CE, Dobesh PP. Renal function considerations for stroke prevention in atrial fibrillation. <i>Am J Med</i>. 2017;130(9):1015-1023. doi: 10.1016/j.amjmed.2017.04.015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28502818/pubmed\" target=\"_blank\" id=\"28502818\">28502818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46. doi: 10.1007/s12028-015-0222-x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frost C, Wang J, Nepal S, et al, &quot;Apixaban, an Oral, Direct Factor Xa Inhibitor: Single-Dose Safety, Pharmacokinetics, Pharmacodynamics and Food Effect in Healthy Subjects,&quot; <i>Br J Clin Pharmacol</i>, 2012, 75(2):476-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/22759198/pubmed\" target=\"_blank\" id=\"22759198\">22759198</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldhaber SZ, Leizorovicz A, Kakkar AK, et al, &ldquo;Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients,&rdquo; <i>N Engl J Med</i>, 2011, 365(23):2167-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/22077144/pubmed\" target=\"_blank\" id=\"22077144\">22077144</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Granger CB, Alexander JH, McMurray JJ, et al, &quot;Apixaban versus Warfarin in Patients With Atrial Fibrillation,&quot; <i>N Engl J Med</i>, 2011, 365(11):981-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/21870978/pubmed\" target=\"_blank\" id=\"21870978\">21870978</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i>. 2015;17(10):1467-1507. doi: 10.1093/europace/euv309.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/26324838/pubmed\" target=\"_blank\" id=\"26324838\">26324838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2015;46(7):2032-2060. doi: 10.1161/STR.0000000000000069.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/26022637/pubmed\" target=\"_blank\" id=\"26022637\">26022637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). <i>Kidney International.</i> 2011;80:572&ndash;586. doi: 10.1038/ki.2011.223.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/21750584/pubmed\" target=\"_blank\" id=\"21750584\">21750584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hohnloser SH, Hijazi Z, Thomas L, et al, &ldquo;Efficacy of Apixaban When Compared With Warfarin in Relation to Renal Function in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial,&rdquo; <i>Eur Heart J</i>, 2012, 33(22):2821-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/22933567/pubmed\" target=\"_blank\" id=\"22933567\">22933567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hull RD, Lip G. Overview of the treatment of lower extremity deep vein thrombosis (DVT). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 18, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26949430\"></a>Ikeda K, Tachibana H. Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation. <i>J Arrhythm</i>. 2016;32(1):42-50. doi: 10.1016/j.joa.2015.08.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/26949430/pubmed\" target=\"_blank\" id=\"26949430\">26949430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>. doi:10.1161/CIR.0000000000000041.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/22315268/pubmed\" target=\"_blank\" id=\"22315268\">22315268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/26867832/pubmed\" target=\"_blank\" id=\"26867832\">26867832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24788967\"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/24788967/pubmed\" target=\"_blank\" id=\"24788967\">24788967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27643979\"></a>Kufel WD, Zayac AS, Lehmann DF, Miller CD. Clinical application and pharmacodynamic monitoring of apixaban in a patient with end-stage renal disease requiring chronic hemodialysis. <i>Pharmacotherapy</i>. 2016;36(11):e166-e171. doi: 10.1002/phar.1836.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/27643979/pubmed\" target=\"_blank\" id=\"27643979\">27643979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29302288\"></a>Lanau N, Mareque J, Giner L, Zabalza M. Direct oral anticoagulants and its implications in dentistry. A review of literature. <i>J Clin Exp Dent</i>. 2017:9(11):e1346-e1354.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29302288/pubmed\" target=\"_blank\" id=\"29302288\">29302288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lassen MR, Gallus A, Raskob GE, et al, &ldquo;Apixaban versus Enoxaparin for Thromboprophylaxis After Hip Replacement,&rdquo; <i>N Engl J Med</i>, 2010a, 363(26):2487-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/21175312/pubmed\" target=\"_blank\" id=\"21175312\">21175312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lassen MR, Raskob GE, Gallus A, et al, &ldquo;Apixaban or Enoxaparin for Thromboprophylaxis After Knee Replacement,&rdquo; [published correction appears in <i>N Engl J Med</i>, 2009;361(18):1814]. <i>N Engl J Med</i>, 2009, 361(6):594-604.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/19657123/pubmed\" target=\"_blank\" id=\"19657123\">19657123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lassen MR, Raskob GE, Gallus A, et al, &ldquo;Apixaban Versus Enoxaparin for Thromboprophylaxis After Knee Replacement (ADVANCE-2): A Randomised Double-Blind Trial,&rdquo; <i>Lancet</i>, 2010b, 375(9717):807-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/20206776/pubmed\" target=\"_blank\" id=\"20206776\">20206776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manning WJ. Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 18, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2016;14(6):1308-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/27299806/pubmed\" target=\"_blank\" id=\"27299806\">27299806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28302754\"></a>Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Apixaban pharmacokinetics at steady state in hemodialysis patients. <i>J Am Soc Nephrol</i>. 2017;28(7):2241-2248. doi: 10.1681/ASN.2016090980.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28302754/pubmed\" target=\"_blank\" id=\"28302754\">28302754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raval AN, Cigarroa JE, Chung MK, et al; American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Quality of Care and Outcomes Research. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association [published corrections appear in <i>Circulation</i>. 2017;135(10):e647; <i>Circulation</i>. 2017;135(24):e1144]. <i>Circulation</i>. 2017;135(10):e604-e633. doi:10.1161/CIR.0000000000000477.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28167634/pubmed\" target=\"_blank\" id=\"28167634\">28167634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sharma A, Chatterjee S, Lichstein E, et al, &ldquo;Extended Thromboprophylaxis for Medically Ill Patients With Decreased Mobility: Does It Improve Outcomes?&rdquo; <i>J Thromb Haemost</i>, 2012, 10(10):2053-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/22863355/pubmed\" target=\"_blank\" id=\"22863355\">22863355</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26331581\"></a>Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. <i>J Clin Pharmacol</i>. 2016;56(5):628-636. doi: 10.1002/jcph.628.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/26331581/pubmed\" target=\"_blank\" id=\"26331581\">26331581</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 85642 Version 164.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F15868354\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F15881499\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14471661\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F14478981\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F14479016\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F14479017\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14479013\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14479014\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F46888094\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F15869945\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F15881025\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F15869944\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14479020\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14478984\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50287188\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14478979\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F14478992\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F14478988\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F14478989\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F14642518\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F14642516\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F14478997\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F15868175\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14478985\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14478987\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14479022\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F50847165\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F14479000\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F14479002\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570441\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059506\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/85642|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=apixaban-patient-drug-information\" class=\"drug drug_patient\">Apixaban: Patient drug information</a></li></ul></div></div>","javascript":null}